Ori Biotech

A leading academic cancer research center put IRO® up against a control process they had refined in-house for over a decade. The center runs a portfolio of internal and partnered CAR-T programs, focused on translating breakthroughs into reproducible, scalable manufacturing that increases clinical and commercialization success. The result was consistent, measurable biological improvement, driven by precise process control. Don't just take our word for it. Book a demo and see it against your own process ➡️ https://lnkd.in/eXEXEGZZ

When you use the wrong tool, you don't get the outcome you're looking for. In CGT, legacy platforms were built for a different job. Applying that same approach to advanced therapy development means working with equipment that wasn't calibrated for the sensitivity and specificity that it demands. The result is variability you spend time correcting. IRO® was purpose-built for cell therapy, with the precision and process control to protect your biology at every stage, from development through commercial scale. Better tools mean better control. Choose IRO. Learn more ➡️ https://oribiotech.com/

New results from a Phase 1 trial show an autologous T-cell therapy reaching brain tumors in children through the bloodstream, sparing kids the invasive delivery typical cancer treatments require. Led by Children's National Hospital and published in Nature Medicine, the trial treated 33 children with T-cells engineered from their own blood. For patients who have historically had very few options, it's an encouraging early sign of cell therapy working in solid tumors. Read more ➡️ https://lnkd.in/gXsrB66E Nature Portfolio

The world's first CAR-T therapy approved for a solid tumor is now available in China. The first international patient to receive it has just begun treatment. Josh, 59, traveled from New Zealand to Shanghai with advanced gastric cancer after conventional treatment options at home became increasingly limited. Biomarker testing confirmed he was eligible for Satri-cel. Satri-cel's approval came days before Josh began his treatment at Jiahui International Cancer Center. His cells have been collected and are now being manufactured, with infusion scheduled in the coming weeks. Getting CAR-T to work in solid tumors has been one of the hardest problems in the field, and Satri-cel's approval is a significant milestone for patients everywhere. Thank you to Jiahui Health 嘉会医疗 for sharing the news ➡️ https://lnkd.in/g9EQj4ZD

University of Pennsylvania Perelman School of Medicine researchers have built an AI framework that finds new CAR-T targets in just weeks, marking a significant step toward extending the therapy beyond blood cancers. Published in Cell Press, the human-in-the-loop approach pairs scientists' expertise with large language models to sift through thousands of potential targets. Read more ➡️ https://lnkd.in/gBrezZMR 

New ten-year data offer the clearest sign yet that CAR-T can cure patients with B-cell lymphoma. In a long-term follow-up of the CTL019 (tisagenlecleucel) trial, no relapses occurred beyond 5.4 years, and approximately one third of patients remained in continuous remission at ten years. For heavily pre-treated patients with disease usually considered incurable, a single infusion producing a decade-long remission is a tremendous clinical outcome. 🔗 https://lnkd.in/ey-sdrkz

Your equipment should serve your process. Too often in CGT manufacturing, it's the other way around. Legacy platforms dictate how scientists work, shaping protocols around equipment limitations rather than biology. IRO® was purpose-built to put CGT teams in control, with adjustable mixing, tunable process parameters, and real-time monitoring across every run. Book a demo and see why our partners choose IRO ➡️ https://lnkd.in/eXEXEGZZ

The science is incredible, but the business model still needs work. That's how Jason C. Foster, our CEO, summed up the state of cell and gene therapy in the latest Roving Reporter episode from IBTV and The Medicine Maker. Regeneron's recent approval of a gene therapy for inherited deafness, now being made available to patients in the US for free, shows both sides of where the field stands. The science is delivering for patients in areas of high unmet need, while the cost of developing and producing these therapies keeps the economics from working. Bringing that cost down through scalable, automated manufacturing is what will make the commercial model sustainable. Watch the full interview: https://lnkd.in/eND39vN4

Maureen spent 46 years travelling the world as a flight attendant. Last year, her own T-cells made the trip that may have saved her life. Maureen and her husband Rob had settled into what she called a "fabulous retirement" in Georgia. Then a routine wellness visit in August 2024 flagged an abnormal white blood cell count. Within days, doctors suspected acute lymphocytic leukemia. For two months, Rob drove her to the clinic every other day while she wore a chemotherapy infusion pump around the clock. It wasn't enough. The cancer remained. Her doctor at Northside Hospital recommended CAR-T cell therapy. Maureen's T cells were collected in Georgia, shipped to a manufacturing laboratory in England for genetic modification, and flown back for infusion. She received her engineered cells in spring 2025, she is now recovering, and the retirement she and Rob had planned is back within reach. Thank you to Northside Hospital for sharing Maureen's story ➡️ https://lnkd.in/e66pAnGH 

The FDA has proposed a rule that could make distributed cell therapy manufacturing simpler to operate, letting hub-and-spoke networks register as a single establishment rather than site-by-site. For cell and gene therapy, decentralized and point-of-care models depend on running multiple sites under unified oversight. Registering each unit individually has been an administrative drag. Aligning registration with how distributed manufacturing actually works removes some of that friction. Units can be added, relocated, or removed through a streamlined update process. This is the regulatory groundwork needed to make scalable, closer-to-patient production viable. Read the proposed rule ➡️ https://lnkd.in/ef4SVfFz